CN Patent
CN101180071A — 抑制蛋白酶体的组合物
Assigned to Onyx Pharmaceuticals Inc · Expires 2008-05-14 · 18y expired
What this patent protects
包含一种或多种几乎不溶解的蛋白酶体抑制剂和环糊精,特别是取代环糊精的组合物,其显著增加了这些蛋白酶体抑制剂的溶解度并促进它们的给药。这些组合物任选包含缓冲剂。还公开了使用这些组合物的治疗方法。
USPTO Abstract
包含一种或多种几乎不溶解的蛋白酶体抑制剂和环糊精,特别是取代环糊精的组合物,其显著增加了这些蛋白酶体抑制剂的溶解度并促进它们的给药。这些组合物任选包含缓冲剂。还公开了使用这些组合物的治疗方法。
Drugs covered by this patent
- Kyprolis (carfilzomib) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.